Peer-reviewedLicence not statedActa Pharmacologica Sinica
Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
4 affiliations
- 1Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203 China
- 2University of Chinese Academy of Sciences, Beijing, 100049 China
- 3State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203 China
- 4Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research, Institute for Drug Discovery, Yantai, 264117 China
Related
- Crucial Role of Lymphocytes in the Therapeutic Efficacy of Dendritic Cell Immunotherapy for Advanced Hepatocellular Carcinoma
- Dendritic cells as master regulators of the T-cell axis in sepsis: mechanisms and therapeutic implications
- Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications
- 921 Hybrid lipid nanoparticles enable in situ and ex vivo dendritic cell-based cancer immunotherapy
- BAP31 Facilitates TGF-β Trafficking and Secretion and Promotes Dendritic Cell Dysfunction in Cervical Cancer
BibTeX
@article{wang2026dendritic,
title = {{Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting}},
author = {Rong Wang and Yi Chen and Yan-fen Fang},
journal = {Acta Pharmacologica Sinica},
year = {2026},
month = jul,
doi = {10.1038/s41401-026-01868-9},
url = {https://doi.org/10.1038/s41401-026-01868-9},
}
RIS
TY - JOUR
TI - Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
AU - Rong Wang
AU - Yi Chen
AU - Yan-fen Fang
PY - 2026
DA - 2026/07/09
JO - Acta Pharmacologica Sinica
DO - 10.1038/s41401-026-01868-9
UR - https://doi.org/10.1038/s41401-026-01868-9
SN - 1671-4083
SN - 1745-7254
ER -